Clinical Trials Logo

Clinical Trial Summary

Colorectal cancer is one of the most common causes of cancer-related death. Early diagnosis is extremely important in terms of treatment and mortality. In this study, we investigated the diagnostic value of serum autotaxin levels in colorectal cancer.


Clinical Trial Description

Colorectal cancer (CRC) is the third most common type of cancer worldwide. Among the causes of death due to cancer; it is the second most common among both genders with a rate of 9.2% after lung cancer . Early detection of the disease is important for survival. National screening programs attempt to detect this disease at an early stage. Autotaxin (ATX) molecule is a member of the nucleotide pyrophosphatase/phosphodiesterase enzyme family (ENNP), It is secreted at 125 kDa, has lysophospholipase D activity in the lysophosphatidic acid (LPA) pathway, and is located at the 24th locus of the long arm of the 8th chromosome. This is also called ENPP2. It was discovered to be an autocrine motility-stimulating factor released by human melanoma A-2058 cells . Lysophosphatidic acid (LPA) is a lipid signalling molecule located in the cell membrane. LPA functions as an autocrine/paracrine messenger through at least six G protein-coupled receptors (GPCR) known as LPA 1-6. It plays physiologically important roles in various cellular processes, including wound healing, differentiation, cell proliferation, and migration. The role of ATX in the bioactivity of LPA is correlated with the lysophosphatidyl-D (lysoPLD) activity of ATX. ATX molecule; With this enzyme activity, it plays a fundamental role in the conversion of lysophosphatidylcholine to lysophosphatidic acid . Many studies have demonstrated the biological effects of the autotaxin-lysophosphatidic acid (ATX-LPA) signalling pathway in cancer. In vitro and in vivo studies have shown that increased ATX-LPA signalling contributes to cancer initiation and progression. Current evidence supports the role of the ATX-LPA signalling pathway in the proliferation, invasion, adhesion, and angiogenesis of cells, and is effective in cancer development and metastasis. Increased ATX expression has been reported in various cancers, such as glioblastoma, hepatocellular and thyroid carcinomas, breast, pancreatic, colon, and hematological cancers . The ATX molecule has the feature of being a molecule that will be effective in the future, not only in the diagnosis of cancer, but also in the treatment process and to be studied extensively. in this study, we aimed to examine the diagnostic and biological behaviour relationship between serum ATX levels and colorectal cancer and to determine the cut-off value for serum ATX levels in colorectal cancer. Serum ATX levels were compared between the patient and control groups. ATX levels were analysed in subgroups formed according to the demographic, clinical, pathological, and laboratory characteristics of the patient group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06091592
Study type Observational
Source Diskapi Yildirim Beyazit Education and Research Hospital
Contact
Status Completed
Phase
Start date December 30, 2020
Completion date December 25, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05074966 - The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts Phase 3
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Completed NCT04551014 - Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm N/A
Completed NCT04551001 - Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy N/A
Recruiting NCT04270500 - The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period N/A
Recruiting NCT03667911 - Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy N/A
Not yet recruiting NCT04073680 - A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03567850 - Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC N/A
Recruiting NCT05870332 - Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
Completed NCT04534218 - Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer Phase 2
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Completed NCT04195646 - Computer Aided Detection of Polyps During Colonoscopy Procedures N/A
Not yet recruiting NCT03261752 - New Genes in the Carcinogenesis of Colorectal Cancer
Not yet recruiting NCT03618329 - Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM. N/A
Terminated NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Phase 1